Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2006 Jun;77(6):712.
doi: 10.1136/jnnp.2006.089839.

Anti-myelin antibodies in multiple sclerosis: clinically useful?

C H Polman, J Killestein
Editorial

Anti-myelin antibodies in multiple sclerosis: clinically useful?

C H Polman et al. J Neurol Neurosurg Psychiatry. 2006 Jun.

Abstract

Anti‐myelin antibodies may have predictive clinical value, but striking correlations as reported earlier are unlikely

PubMed Disclaimer

Conflict of interest statement

Chris Polman: I report having received the following: consulting fees from Biogen Idec, Schering AG, Teva, Serono, Novartis, Antisense, and GlaxoSmithKline; lecture fees from Biogen Idec, Schering AG, and Teva; and grant support from Biogen Idec, Schering AG, Wyeth, and GlaxoSmithKline. Joep Killestein: I have worked with the companies that market drugs for MS (Schering AG, Biogen Idec, Serono, Teva) and with some companies that have development programs for future drugs in MS.

Competing interests: None declared.

Comment on

References

    1. Berger T, Rubner P, Schautzer F.et al Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003349(2)139–145. - PubMed
    1. Lampasona V, Frianciotta D, Furlan R.et al Similar low frequency of anti‐MOG IgG and IgM in MS patients and healthy subjects. Neurology 200462(11)2092–2094. - PubMed
    1. Lim E T, Berger T, Reindl M.et al Anti‐myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 200511(4)492–494. - PubMed
    1. Mantegazza R, Cristaldini P, Bernasconi P.et al Anti‐MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 200416(4)559–565. - PubMed
    1. Lalive P H, Menge T, Delarasse C.et al Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006103(7)2280–2285. - PMC - PubMed